Humira approved for juvenile rheumatoid arthritis

Abbott's Humira (adalimumab) has been approved by the Food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis.

JVA joins other indications including chronic plaque psoriasis, rheumatoid arthritis in adults, and Crohn's disease.